New hope for aggressive lymphoma: drug combo shows promise in early trial
NCT ID NCT02213913
First seen Mar 26, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tested a combination of the drug lenalidomide with standard chemotherapy (called DA-EPOCH-R) in 55 people with a fast-growing type of B-cell lymphoma linked to the MYC gene. The goal was to find the safest dose and see if the combo helps keep the cancer from growing or coming back. While not a cure, the approach aims to better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526, United States
-
Illinois Cancer Care
Peoria, Illinois, 61615, United States
-
NorthShore University HealthSystem
Evanston, Illinois, 60201, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Maryland
Baltimore, Maryland, 21202, United States
Conditions
Explore the condition pages connected to this study.